We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 39.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMI
76
DELISTED
Foundation Medicine, Inc.
FMI
$2.11M 0.03%
+78,162
New +$1.98M
MDGL icon
77
Madrigal Pharmaceuticals
MDGL
$12.4B
$2.04M 0.03%
14,286
– –
LJPC
78
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.04M 0.02%
221,631
– –
OSUR icon
79
OraSure Technologies
OSUR
$274M
$2.02M 0.02%
234,664
– –
RIGL icon
80
Rigel Pharmaceuticals
RIGL
$712M
$1.75M 0.02%
48,197
– –
FOLD
81
DELISTED
Amicus Therapeutics
FOLD
$1.61M 0.02%
481,697
– –
ISEE
82
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.56M 0.02%
36,776
– –
AKAO
83
DELISTED
Achaogen Inc
AKAO
$1.4M 0.02%
100,000
– –
GERN icon
84
Geron
GERN
$905M
$1.29M 0.02%
425,981
– –
RCPT
85
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1.02M 0.01%
23,900
– –
TCRT icon
86
Alaunos Therapeutics
TCRT
$4.71M
$986K 0.01%
1,631
– –
XLRN
87
DELISTED
Acceleron Pharma
XLRN
$977K 0.01%
28,765
– –
TSRO
88
DELISTED
TESARO, Inc.
TSRO
$971K 0.01%
31,218
– –
ALNY icon
89
Alnylam Pharmaceuticals
ALNY
$38.1B
$733K 0.01%
11,600
– –
QURE icon
90
uniQure
QURE
$2.76B
$417K 0.01%
30,672
– –
FPRX
91
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$308K ﹤0.01%
19,823
– –
CCXI
92
DELISTED
ChemoCentryx, Inc.
CCXI
$293K ﹤0.01%
50,000
– –
ASMB icon
93
Assembly Biosciences
ASMB
$494M
– –
-6,962
Closed -$535K
PRTA icon
94
Prothena Corp
PRTA
$441M
– –
-230,142
Closed -$8.82M
SVRA icon
95
Savara
SVRA
$1.07B
– –
-42,857
Closed -$2.04M
TVTX icon
96
Travere Therapeutics
TVTX
$5.12B
– –
-197,178
Closed -$4.19M
ICPT
97
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-256,375
Closed -$84.5M
PTLA
98
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-182,591
Closed -$4.73M
AUXL
99
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-58,544
Closed -$1.59M
FURX
100
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-40,309
Closed -$3.51M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Baker Bros. Advisors held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Baker Bros. Advisors withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 43% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Baker Bros. Advisors's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Baker Bros. Advisors added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Baker Bros. Advisors's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Baker Bros. Advisors fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Baker Bros. Advisors's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Baker Bros. Advisors opened 7 new positions and closed 9 in Q2 2014.
  • Baker Bros. Advisors's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.